Zepbound® and Ozempic® are the two most searched names in the GLP-1 category, and they are constantly discussed as if they were competing versions of the same product. They are not. They are two different molecules, made by two different companies, and approved by the FDA for two different jobs.
Ozempic® is a type 2 diabetes medication. Zepbound® is not, and never has been. Zepbound® is Eli Lilly's brand of tirzepatide, licensed for chronic weight management and for obstructive sleep apnea. Ozempic® is Novo Nordisk's brand of semaglutide, licensed for blood sugar control in type 2 diabetes plus cardiovascular and kidney risk reduction. The confusion is understandable, because each molecule is sold under a second brand name for the other purpose — and those second brands are where the true like-for-like comparisons live, in Zepbound® vs Wegovy® and in Mounjaro® vs Ozempic®.
This guide sets out what each drug is actually approved to do, what the head-to-head trial evidence shows, how they are given, and what has changed since 2024 — which is a great deal.
No. This is the single most common question about the two drugs, and the short answer is that they share a family resemblance and almost nothing else. Both belong to the incretin mimetic class, both are injected once weekly, and both work partly by acting on the GLP-1 receptor. From there they diverge: different molecules, different manufacturers, different receptor targets and — most importantly for anyone choosing between them — different FDA-approved indications.
| Zepbound® (tirzepatide) | Ozempic® (semaglutide) | |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA-approved for | Chronic weight management in adults with obesity or overweight with a weight-related condition; and moderate-to-severe obstructive sleep apnea in adults with obesity | Glycemic control in type 2 diabetes; reducing major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease |
| Approved for diabetes? | No. It has never carried a diabetes indication | Yes — that is its primary indication |
| Same molecule, other brand | Mounjaro® — tirzepatide for type 2 diabetes | Wegovy® — semaglutide for weight management |
| How it works | Dual agonist: activates both GIP and GLP-1 receptors | Single agonist: activates the GLP-1 receptor only |
| Dosing | Once weekly by injection. Maintenance doses of 5, 10 or 15 mg (10 or 15 mg for sleep apnea) | Once weekly by injection. Maintenance doses of 0.5, 1 or 2 mg. Also available as a daily tablet since May 2026 |
| Boxed warning | Thyroid C-cell tumors (rodent studies) | Thyroid C-cell tumors (rodent studies) |
For practitioners: the indication mismatch is not a technicality. Prescribing tirzepatide for glycemic control means prescribing Mounjaro®, not Zepbound®, and the distinction drives prior authorization, formulary placement and payer coverage far more than clinical preference does. The same logic applies in reverse when a patient on Ozempic® asks about weight management: Wegovy® is the semaglutide product carrying that indication.
Neither medication is insulin. Both belong to a class of drugs called incretin mimetics, which imitate hormones the body releases after eating. They increase insulin secretion when blood glucose is high, slow the rate at which the stomach empties, and reduce appetite. Because they only stimulate insulin when glucose is already elevated, they carry a relatively low risk of hypoglycemia on their own — though that risk rises when they are combined with insulin or a sulfonylurea.
Ozempic® is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Beyond blood sugar, it carries two outcome-based indications. Since 2020 it has been approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. And on January 28, 2025 it became the first GLP-1 receptor agonist approved to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Zepbound® is approved for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. On December 20, 2024 it also became the first prescription medicine ever approved for moderate-to-severe obstructive sleep apnea in adults with obesity — an indication no semaglutide product holds. In the SURMOUNT-OSA trials, participants not using positive airway pressure therapy averaged about 25 fewer breathing interruptions per hour on tirzepatide compared with 5 on placebo; among those using PAP therapy, the figures were 29 versus 6.
That sleep apnea approval is the clearest illustration of why these two drugs are not substitutes for one another. Zepbound® is licensed on the strength of what happens when body weight comes down. Ozempic® is licensed on the strength of what happens to blood glucose, the heart and the kidneys.
Most side effects are shared, because they follow from the class mechanism rather than from either specific molecule. The common ones — nausea, vomiting, diarrhea, constipation and reduced appetite — are most pronounced during dose escalation and typically ease as the body adapts.
Both products also carry the same boxed warning: in rodents, these molecules caused thyroid C-cell tumors. Whether that translates to humans is unknown, but both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
One widely repeated claim needs correcting: Ozempic® is not flagged for causing kidney problems. Since January 2025 it has been approved to slow kidney decline in type 2 diabetes with chronic kidney disease. What the labeling does note is that dehydration from severe gastrointestinal side effects can cause acute kidney injury in anyone taking a GLP-1 — a consequence of fluid loss, not of the drug acting on the kidney.
On cardiovascular effects, the picture has also changed. It was once accurate to say tirzepatide's cardiovascular profile was unknown. The SURPASS-CVOT trial, involving more than 13,000 participants, reported in December 2025, and on August 28, 2026 Mounjaro® gained an indication for cardiovascular risk reduction in adults with type 2 diabetes. That result was non-inferiority rather than superiority, and the indication belongs to Mounjaro®, not to Zepbound® — but the molecule now has outcome data behind it.
One further update patients often ask about: the warning regarding suicidal ideation was removed from tirzepatide labeling on January 13, 2026 at the FDA's request, following a review spanning 91 clinical trials and roughly 2.2 million users.
This is where the internet gets things wrong most often, usually by mixing up which trial compared what. There are two direct head-to-head trials of these molecules, and they tested different brands at different doses for different purposes.
| Trial | What it compared | Result |
|---|---|---|
| SURPASS-2 NEJM, 2021 · 1,879 adults with type 2 diabetes · 40 weeks | Tirzepatide 5, 10 and 15 mg against semaglutide 1 mg — the two molecules at diabetes doses | A1C: −2.09%, −2.37%, −2.46% vs −1.86% Weight: −8.5%, −11.0%, −13.1% vs −6.7% Tirzepatide was superior on both, at every dose |
| SURMOUNT-5 NEJM, 2025 · 72 weeks | Zepbound® against Wegovy® — the two weight-management brands | Weight: −20.2% with tirzepatide vs −13.7% with semaglutide |
| SURMOUNT-1 NEJM, 2022 · 2,539 adults · 72 weeks | Tirzepatide 5, 10 and 15 mg against placebo, for weight management | Weight: −15.0%, −19.5%, −20.9% vs −3.1% on placebo |
Average weight reduction in the two head-to-head trials
SURPASS-2 — diabetes brands, diabetes doses, 40 weeks
SURMOUNT-5 — weight-management brands, 72 weeks
Bars are scaled to a 25% maximum. The two trials used different doses, durations and patient populations, so the pairs should be read within each trial rather than across them.
Tirzepatide outperformed semaglutide in both trials. But two caveats matter. First, SURPASS-2 compared the diabetes brands at diabetes doses; it is evidence about the molecules, not a licence to describe Zepbound® as a better blood sugar drug, since Zepbound® has no A1C indication at all. Second, SURMOUNT-5 compared Zepbound® to Wegovy®, not to Ozempic® — the trial most often cited on this comparison is not actually about Ozempic®.
Clinically, group averages are also a poor guide to any individual result. Response varies widely, tolerability often decides the maximum achievable dose, and the drug a patient can obtain and afford consistently tends to outperform the one that trial data favors on paper.
Ozempic® is approved for type 2 diabetes in adults. Zepbound® is not approved for diabetes of any type — for tirzepatide in type 2 diabetes, the approved product is Mounjaro®.
Neither molecule is approved for type 1 diabetes. People with type 1 diabetes produce little or no insulin at all, and these medications work by amplifying the body's own insulin response rather than replacing it. Insulin therapy remains the standard of care, and GLP-1 receptor agonists are not a substitute for it.
In type 2 diabetes, these agents are generally not first-line pharmacotherapy; they are introduced when lifestyle measures and first-line therapy have not achieved the target. They are typically avoided in patients with a history of pancreatitis, and used with particular caution in anyone with a history of diabetic ketoacidosis.
Both are given once weekly by subcutaneous injection — into the fat just beneath the skin of the abdomen, thigh or upper arm, with sites rotated to avoid lumps and skin thickening. The injection can be taken at any time of day, with or without food, and the day of the week can be changed if the interval rules on the labeling are respected. Self-injection is daunting for most people at first and routine for nearly all of them within a few weeks.
What has changed is the range of delivery formats. Zepbound® is now supplied as a single-dose pen, a single-dose vial, a multi-dose vial, and a single-patient-use KwikPen holding four weekly doses, which was FDA-approved in late January 2026 and launched on February 23, 2026. Full details of the escalation schedule are set out in our tirzepatide dosage guide.
Ozempic® is supplied as a multi-dose pen with a maximum dose of 2 mg once weekly; the semaglutide dosage chart covers the titration steps. As of May 4, 2026 semaglutide is also available in US pharmacies as a daily oral tablet under the Ozempic® name, in 1.5 mg, 4 mg and 9 mg strengths, for glycemic control and cardiovascular risk reduction in type 2 diabetes — a second oral semaglutide alongside the original Rybelsus®, as covered in our guide to oral versus injectable semaglutide. Zepbound® has no oral formulation.
They are not taken together. Both act on the GLP-1 receptor, so combining them duplicates the same mechanism with no added benefit and a meaningfully higher risk of gastrointestinal side effects. No guideline supports the combination, and no trial has evaluated it.
Switching between them is a different matter and happens often — usually because insurance coverage changes, because supply changes, because a patient's clinical situation moves from a weight indication to a diabetes one, or because side effects were intolerable on one and worth retrying on the other. A switch is a prescriber decision, not a straight swap: the two products are dosed on entirely different scales, so a patient moving between them restarts titration at the new product's starting dose and works up again. Patients should never attempt to convert a dose themselves.
Popularity is driven less by trial results than by four practical factors: how well the drug works for that individual, how tolerable the side effects are, how convenient the administration is, and what it costs. Cost and coverage, in practice, decide more prescriptions than efficacy data does.
Both manufacturers now run direct self-pay channels that have reshaped the pricing conversation. Lilly lists Zepbound® through LillyDirect at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg, with a refill required within 45 days. Novo Nordisk announced a price reduction for Ozempic® on February 24, 2026 and expanded telehealth distribution in March 2026; the oral tablet is offered through NovoCare® Pharmacy at $149, $199 and $299 a month by strength, and as little as $25 a month for many insured patients.
Public attention has also followed the trial headlines. When SURMOUNT-5 was published in 2025 showing tirzepatide producing greater weight loss than semaglutide, interest in the Lilly products rose sharply — though, as noted above, that trial compared Zepbound® with Wegovy® rather than with Ozempic®.
For people with type 2 diabetes, steadier glycemic control means fewer of the daily symptoms of hyperglycemia — frequent urination, persistent thirst, blurred vision and fatigue. Ozempic®'s cardiovascular and kidney indications extend that further: the two complications people with diabetes most fear are precisely the ones it is now licensed to help reduce.
For people treated for obesity, the quality-of-life gains recorded in the tirzepatide trials have been about mobility, joint comfort, sleep and the day-to-day burden of carrying excess weight. The obstructive sleep apnea indication is the most concrete example: fewer breathing interruptions overnight translates directly into daytime alertness for people whose sleep has been fragmented for years.
Both medications work alongside diet and physical activity rather than replacing them, and both work only while they are being taken. Weight regain after discontinuation is well documented, which is why long-term treatment planning — and honest conversation about it at the outset — matters as much as the choice of molecule.
Both product lines have moved substantially. For clinicians tracking the category, and for patients who last read about these drugs a year or two ago, this is the short version.
| Date | Change |
|---|---|
| December 20, 2024 | Zepbound® approved for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for OSA |
| January 28, 2025 | Ozempic® approved to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease |
| 2025 | SURMOUNT-5 published: tirzepatide −20.2% vs semaglutide −13.7% body weight at 72 weeks |
| December 2025 | SURPASS-CVOT reports cardiovascular outcome data for tirzepatide in more than 13,000 participants |
| January 13, 2026 | Suicidal ideation warning removed from tirzepatide labeling at FDA request |
| February 23, 2026 | Zepbound® KwikPen launches — a single-patient-use pen holding four weekly doses |
| February 24, 2026 | Novo Nordisk announces an Ozempic® price reduction; telehealth distribution expands in March |
| May 4, 2026 | An oral semaglutide tablet becomes available in US pharmacies under the Ozempic® name (1.5, 4 and 9 mg) |
| August 28, 2026 | Mounjaro® — tirzepatide for type 2 diabetes — approved to reduce cardiovascular risk |
For practices already offering or considering a medical weight management service, the pace of change is itself the point. Indications, formulations and pricing in this category have shifted roughly every quarter for two years, and patient questions move with them. The Medical Weight Management® Library tracks these developments across the GLP-1 category.
Get IAPAM’s Quick Start Checklist for starting or integrating a GLP-1 weight loss service — the clinical, operational and business decisions to make before you see your first patient.
What’s Inside the Checklist
For licensed practitioners: MD/DO, NP, APRN/CRNA, PA, DMD/DDS, RN
Enter your details and we’ll email your copy.
No. They are two different molecules made by two different companies and approved for two different purposes. Zepbound® is tirzepatide, made by Eli Lilly, and is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Ozempic® is semaglutide, made by Novo Nordisk, and is approved for type 2 diabetes, cardiovascular risk reduction and slowing kidney decline.
No. Zepbound® has never been approved for type 2 diabetes. The same molecule, tirzepatide, is approved for type 2 diabetes under a different brand name, Mounjaro®. If a prescriber wants tirzepatide for diabetes, Mounjaro® is the product with that indication.
Zepbound® has no A1C indication, so it is not prescribed to control blood sugar. The tirzepatide molecule does lower A1C: in the SURPASS-2 trial, tirzepatide reduced A1C by 2.09% to 2.46% depending on dose, compared with 1.86% for semaglutide 1 mg. That trial used the diabetes brands at diabetes doses, not Zepbound®.
In the only direct weight-management comparison, SURMOUNT-5, tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide. That trial compared Zepbound® with Wegovy®, which is the weight-management brand of semaglutide, not with Ozempic®.
No. Both act on the GLP-1 receptor, so taking them together duplicates the same mechanism without added benefit and increases the risk of gastrointestinal side effects. They are not prescribed in combination.
Yes. An oral semaglutide tablet under the Ozempic® name became available in US pharmacies on May 4, 2026, in 1.5 mg, 4 mg and 9 mg strengths, for glycemic control and cardiovascular risk reduction in adults with type 2 diabetes.
Zepbound® and Ozempic® are not rival versions of one product. One is licensed to treat obesity and the sleep apnea that so often accompanies it; the other is licensed to control blood sugar and to protect the heart and kidneys in people with type 2 diabetes. Comparing them is useful mainly for understanding which question a patient is actually asking — and then pointing them at the right like-for-like comparison.
For practitioners, that distinction is where a medical weight management program either works or creates problems. Selecting the right product for the right indication, titrating safely, monitoring properly and documenting it all is a clinical skill set, not an administrative one. IAPAM's GLP-1 certification training covers exactly that ground, from patient selection through program design.
Explore GLP-1 Certification Training
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. It does not provide dosing instructions. Treatment decisions, product selection, titration and monitoring must be made for each patient by a qualified, licensed prescriber. Always follow current product labeling, your scope of practice, and your state medical and nursing board regulations. If you have questions about your own medication, speak with your physician or healthcare provider.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.